Acceleron Pharma

Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming virtual healthcare investor conferences. Conference Presentation Details: Event: Cowen & Co. 41st Annual Health Care Conference Date/Time: Tuesday, March 2, 2021 at 2:50 p.m. EST Event: B

Acceleron to Participate in Two Upcoming Healthcare Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 25, 2021 at 5:00 p.m. EST to discuss its fourth quarter and full year 2020 financial results. The webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Company's website at acceleronpharma.com. To participate in the conference call, please dial 833-494-1483 (domestic) or 236-714-2620 (internationa

Acceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Bristol-Myers

Bristol-Myers Squibb Co (NYSE: BMY) and its collaborating partner Acceleron Pharma Inc (NASDAQ: XLRN) have announced that Health Canada has approved Reblozyl (luspatercept for injection) to treat anemia in myelodysplastic syndromes (MDS) patients with ring sideroblasts. It is a low-risk subtype of blood cancer in which red blood cells contain a ring of excess iron.

Bristol-Myers, Acceleron's Reblozyl Ok'd In Canada For MDS-Associated Anemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $115 million for the fourth quarter and approximately $274 million for the full year ended December 31, 2020. Acceleron exp

Acceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net Sales

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that Habib Dable, Acceleron's President and Chief Executive Officer, will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 11 at 10:00 a.m. EST, in a virtual format. A live webcast of the presentation will be accessible under “Events and Presentations” in the Investors & Media page of the Company's website at www.acc

Acceleron to Participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021

Biogen

Bio-Rad Laboratories

CVS Health

Horizon Pharma

Moderna

Insulet

QuidelOrtho Corp

Health Care Select Sector SPDR Fund

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Top Healthcare Stocks for January 2021

BioCryst Pharmaceuticals

Halozyme Therapeutics

Teladoc

The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U.S. population has spurred demand for healthcare products and services. The sector continues to undertake several technological advancements for boosting the digital space.

5 Healthcare Stocks That Fared Well in 2020 Amid the Pandemic

Acceleron's (XLRN) investigational therapy sotatercept receives an Orphan designation in Europe for the treatment of patients with pulmonary arterial hypertension. Shares up.

Acceleron's (XLRN) PAH Candidate Gets Orphan Designation in EU

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the European Commission (EC) has granted orphan designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH). “We're thrilled at the European Commission's decision to grant orphan designation to sotater

Acceleron Receives Orphan Designation from the European Commission (EC) for Sotatercept in Pulmonary Arterial Hypertension (PAH)

Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?

Acceleron (XLRN) Up 8.6% Since Last Earnings Report: Can It Continue?

The FDA grants orphan drug designation to Acceleron's (XLRN) ACE-1334 for the treatment of patients with systemic sclerosis.

Acceleron (XLRN) Gets Orphan Drug Tag for ACE-1334 by FDA

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to ACE-1334 for the treatment of patients with systemic sclerosis. The Company intends to initiate a Phase 1b/Phase 2 trial in patients with systemic sc

Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented a set of preliminary interim data from the ongoing SPECTRA Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH). Initial data from the trial, which is designed to assess resting and exercise hemodynamics and peak oxyg

Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented new cardiac and pulmonary function data from the ongoing PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH). Echocardiography data obtained during the PULSAR trial and presented virtually during the American

Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association (AHA) Scientific Sessions

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that updates from the ongoing PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) will be presented at the American Heart Association (AHA) 2020 Scientific Sessions, held virtually Novembe

Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association (AHA) Scientific Sessions

Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q3 2020 Results - Earnings Call Transcript

Acceleron Pharma's (XLRN) CEO Habib Dable On Q3 2020 Results - Quick Version Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2020. “Acceleron has made significant progress this year with continued market expansion and adoption of REBLOZYL, and the finalization of the global regula

Acceleron Reports Third Quarter 2020 Operating and Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $96 million for the third quarter ended September 30, 2020. Acceleron expects to report royalty revenue of approximately $1

Acceleron Announces Third Quarter 2020 REBLOZYL® Net Sales

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that data from six clinical abstracts on REBLOZYL (luspatercept-aamt) will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition held virtually December 5-8, 2020. The ASH presentations include updates from t

Acceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations at the 62nd American Society of Hematology Annual Meeting

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acceleron Pharma (XLRN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting 30,000 to generate strong returns. However, as we know, big investors usually buy stocks with strong fundamentals that can deliver gains both in bull and bear markets, which is why we believe we can profit from imitating them. In this article, we are going to take a look at the smart money sentiment surrounding Acceleron Pharma Inc (NASDAQ:XLRN).

Were Hedge Funds Right About Embracing Acceleron Pharma Inc (XLRN)?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its third quarter 2020 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Company's website at acceleronpharma.com. Individuals can participate in the conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (int

Acceleron to Webcast Third Quarter 2020 Operating and Financial Results on November 5, 2020

Acceleron Pharma Plan For Sotatercept Adds To Buy Conviction

MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. (NASDAQ:XLRN) announced today that Health Canada has approved REBLOZYL® (luspatercept) for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia.1 REBLOZYL® is the first and only erythroid maturation agent in Canada, representing a new class of treatment for eligible patients.1 Beta thalassemia is a rare genetic blood diso

News for Acceleron Pharma Stock (XLRN)